drugset / Trial / NCT01000727

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727

Phase 3 Completed 13026 enrolled GlaxoSmithKline The TIMI Study Group · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).

Timeline

Start
2009-12-01
Primary completion
2014-04-01
Completion
2014-04-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Darapladib Small molecule 160 mg Oral